Total-body PET Imaging for Cancer

Recruiting in Palo Alto (17 mi)

Overseen byLorenzo Nardo, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: University of California, Davis

No Placebo Group

Trial Summary

What is the purpose of this trial?

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Eligibility Criteria

This trial is for adults with certain types of cancer: prostate, neuroendocrine tumors, or breast cancer. Participants must have had a previous imaging study within the last 4 months that suggests metastatic disease. Men over 18 suspected of having prostate cancer recurrence based on PSA levels can also join.

Inclusion Criteria

I was diagnosed with ER-positive breast cancer in the last 6 months.

I am a man over 18 with suspected prostate cancer spread or recurrence, indicated by high PSA levels.

I've had a scan within the last 4 months showing possible cancer spread.

See 4 more

Exclusion Criteria

I am unable to give consent for medical procedures.

I haven't taken tamoxifen in the last 8 weeks or fulvestrant in the last 28 weeks.

Prisoners

See 5 more

Treatment Details

Interventions

18F-FES (Radiotracer)
18F-PSMA (Radiotracer)
68Ga DOTATATE (Radiotracer)

Trial OverviewThe study tests new ways to use the EXPLORER total-body PET/CT scanner with FDA-approved imaging agents (18F-PSMA for prostate cancer, 68Ga DOTATATE for neuroendocrine tumors, and 18F-FES for breast cancer) to improve diagnostic accuracy.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Total-body PET scanExperimental Treatment1 Intervention

All participants will receive a dynamic PET scan for up to 90 minutes. This will be followed by two 30 minutes static PET scans at 3 hours +/-20 minutes and 6 hours +/-20 minutes post injection. Subjects injected with 18F-PSMA or 18F-FES will receive a 40 minute scan at 9 hours +/-20 minutes post injection.

18F-FES is already approved in United States for the following indications:

🇺🇸 Approved in United States as 18F-Fluoroestradiol for: